肝硬化顽固性腹水的治疗进展  

Progress on the treatment of patients with cirrhosis and refractory ascites

作　　者：成美娇 郑伟强 CHENG Mei-jiao;ZHENG Wei-qiang(Department of Infectious Disease,the Affiliated Hospital of Guangdong Medical University,Zhanfiang 524000,Guangdong, CHINA)

机构地区：[1]广东医科大学附属医院感染内科,广东湛江524000

出　　处：《海南医学》2019年第2期252-255,共4页Hainan Medical Journal

基　　金：广东省医学科研基金(编号:A2017455);广东省湛江市财政科技专项竞争性分配项目(编号:2017A01018)

摘　　要：肝硬化失代偿期因严重的钠水潴留可逐渐发展为顽固性腹水。顽固性腹水发生机制仍未完全阐明,并且对限钠、利尿、护肝、补充白蛋白、放腹水等传统治疗措施效果欠佳,死亡率高。本文就顽固性腹水发生机制及治疗方法给予综述。The patients with liver cirrhosis can develop refractory ascites gradually due to severe sodium and water retention. The mechanism of refractory ascites is still not fully elucidated, and the traditional treatment measures such as sodium restriction, diuresis, liver protection, albumin supplementation and ascites are not effective and the mortality rate is high. This article reviews the mechanism and treatment of refractory ascites.

关 键 词：顽固性腹水 特利加压素 托伐普坦 自动低流量腹水泵 腹水超滤浓缩回输术 

分 类 号：R575.2[医药卫生—消化系统]